Comprehensive assessment of variation at the transforming growth factor β type 1 receptor locus and colorectal cancer predisposition

Luis Carvajal-Carmona, Mike Churchman, Carolina Bonilla, Axel Walther, Jeremie H. Lefèvre, David Kerr, Malcolm Dunlop, Richard Houlston, Walter F. Bodmer, Ian Tomlinson

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The role of transforming growth factor β receptor type 1 (TGFBR1) polymorphisms, particularly a coding CGC insertion (rs11466445, TGFBR1*6A/9A) in exon 1, has been extensively investigated in regard to colorectal cancer (CRC) risk. These investigations have generated conflicting results. More recently, allele-specific expression (ASE) of TGFBR1 mRNA has been suggested as predisposing to CRC, with a relative risk of nearly 10-fold and a population attributable risk of ∼10%. Owing to the potential importance of TGFBR1 variants in CRC, we performed a comprehensive examination of tagging SNPs at and around the gene in 3,101 CRC cases and 3,334 controls of northern European ancestry. To test whether rare or subpolymorphic TGFBR1 variants were associated with CRC risk, we sequenced the gene's exons in a subset of patients. We also evaluated TGFBR1 ASE in a panel of CRC cases and controls. Overall, we found no association between TGFBR1 polymorphisms and CRC risk. The rare variant screen did not identify any changes of potentially pathogenic effects. No evidence of greater ASE in cases than controls was detected, and no haplotype around TGFBR1 could account for the ASE reported in other studies. We conclude that neither genetic variation nor ASE at TGFBR1 is likely to be a major CRC risk factor.

Original languageEnglish (US)
Pages (from-to)7858-7862
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume107
Issue number17
DOIs
StatePublished - Apr 27 2010
Externally publishedYes

Fingerprint

Growth Factor Receptors
Transforming Growth Factors
Colorectal Neoplasms
Alleles
Exons
Haplotypes
Genes
Single Nucleotide Polymorphism
Messenger RNA

Keywords

  • Candidate gene
  • Genetic susceptibility
  • Low penetrance
  • TGF signaling
  • Transforming growth factor β receptor type 1 *6A/9A

ASJC Scopus subject areas

  • General

Cite this

Comprehensive assessment of variation at the transforming growth factor β type 1 receptor locus and colorectal cancer predisposition. / Carvajal-Carmona, Luis; Churchman, Mike; Bonilla, Carolina; Walther, Axel; Lefèvre, Jeremie H.; Kerr, David; Dunlop, Malcolm; Houlston, Richard; Bodmer, Walter F.; Tomlinson, Ian.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 107, No. 17, 27.04.2010, p. 7858-7862.

Research output: Contribution to journalArticle

Carvajal-Carmona, Luis ; Churchman, Mike ; Bonilla, Carolina ; Walther, Axel ; Lefèvre, Jeremie H. ; Kerr, David ; Dunlop, Malcolm ; Houlston, Richard ; Bodmer, Walter F. ; Tomlinson, Ian. / Comprehensive assessment of variation at the transforming growth factor β type 1 receptor locus and colorectal cancer predisposition. In: Proceedings of the National Academy of Sciences of the United States of America. 2010 ; Vol. 107, No. 17. pp. 7858-7862.
@article{0a54488ca695498dac6447eff65a6f4d,
title = "Comprehensive assessment of variation at the transforming growth factor β type 1 receptor locus and colorectal cancer predisposition",
abstract = "The role of transforming growth factor β receptor type 1 (TGFBR1) polymorphisms, particularly a coding CGC insertion (rs11466445, TGFBR1*6A/9A) in exon 1, has been extensively investigated in regard to colorectal cancer (CRC) risk. These investigations have generated conflicting results. More recently, allele-specific expression (ASE) of TGFBR1 mRNA has been suggested as predisposing to CRC, with a relative risk of nearly 10-fold and a population attributable risk of ∼10{\%}. Owing to the potential importance of TGFBR1 variants in CRC, we performed a comprehensive examination of tagging SNPs at and around the gene in 3,101 CRC cases and 3,334 controls of northern European ancestry. To test whether rare or subpolymorphic TGFBR1 variants were associated with CRC risk, we sequenced the gene's exons in a subset of patients. We also evaluated TGFBR1 ASE in a panel of CRC cases and controls. Overall, we found no association between TGFBR1 polymorphisms and CRC risk. The rare variant screen did not identify any changes of potentially pathogenic effects. No evidence of greater ASE in cases than controls was detected, and no haplotype around TGFBR1 could account for the ASE reported in other studies. We conclude that neither genetic variation nor ASE at TGFBR1 is likely to be a major CRC risk factor.",
keywords = "Candidate gene, Genetic susceptibility, Low penetrance, TGF signaling, Transforming growth factor β receptor type 1 *6A/9A",
author = "Luis Carvajal-Carmona and Mike Churchman and Carolina Bonilla and Axel Walther and Lef{\`e}vre, {Jeremie H.} and David Kerr and Malcolm Dunlop and Richard Houlston and Bodmer, {Walter F.} and Ian Tomlinson",
year = "2010",
month = "4",
day = "27",
doi = "10.1073/pnas.1002816107",
language = "English (US)",
volume = "107",
pages = "7858--7862",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "17",

}

TY - JOUR

T1 - Comprehensive assessment of variation at the transforming growth factor β type 1 receptor locus and colorectal cancer predisposition

AU - Carvajal-Carmona, Luis

AU - Churchman, Mike

AU - Bonilla, Carolina

AU - Walther, Axel

AU - Lefèvre, Jeremie H.

AU - Kerr, David

AU - Dunlop, Malcolm

AU - Houlston, Richard

AU - Bodmer, Walter F.

AU - Tomlinson, Ian

PY - 2010/4/27

Y1 - 2010/4/27

N2 - The role of transforming growth factor β receptor type 1 (TGFBR1) polymorphisms, particularly a coding CGC insertion (rs11466445, TGFBR1*6A/9A) in exon 1, has been extensively investigated in regard to colorectal cancer (CRC) risk. These investigations have generated conflicting results. More recently, allele-specific expression (ASE) of TGFBR1 mRNA has been suggested as predisposing to CRC, with a relative risk of nearly 10-fold and a population attributable risk of ∼10%. Owing to the potential importance of TGFBR1 variants in CRC, we performed a comprehensive examination of tagging SNPs at and around the gene in 3,101 CRC cases and 3,334 controls of northern European ancestry. To test whether rare or subpolymorphic TGFBR1 variants were associated with CRC risk, we sequenced the gene's exons in a subset of patients. We also evaluated TGFBR1 ASE in a panel of CRC cases and controls. Overall, we found no association between TGFBR1 polymorphisms and CRC risk. The rare variant screen did not identify any changes of potentially pathogenic effects. No evidence of greater ASE in cases than controls was detected, and no haplotype around TGFBR1 could account for the ASE reported in other studies. We conclude that neither genetic variation nor ASE at TGFBR1 is likely to be a major CRC risk factor.

AB - The role of transforming growth factor β receptor type 1 (TGFBR1) polymorphisms, particularly a coding CGC insertion (rs11466445, TGFBR1*6A/9A) in exon 1, has been extensively investigated in regard to colorectal cancer (CRC) risk. These investigations have generated conflicting results. More recently, allele-specific expression (ASE) of TGFBR1 mRNA has been suggested as predisposing to CRC, with a relative risk of nearly 10-fold and a population attributable risk of ∼10%. Owing to the potential importance of TGFBR1 variants in CRC, we performed a comprehensive examination of tagging SNPs at and around the gene in 3,101 CRC cases and 3,334 controls of northern European ancestry. To test whether rare or subpolymorphic TGFBR1 variants were associated with CRC risk, we sequenced the gene's exons in a subset of patients. We also evaluated TGFBR1 ASE in a panel of CRC cases and controls. Overall, we found no association between TGFBR1 polymorphisms and CRC risk. The rare variant screen did not identify any changes of potentially pathogenic effects. No evidence of greater ASE in cases than controls was detected, and no haplotype around TGFBR1 could account for the ASE reported in other studies. We conclude that neither genetic variation nor ASE at TGFBR1 is likely to be a major CRC risk factor.

KW - Candidate gene

KW - Genetic susceptibility

KW - Low penetrance

KW - TGF signaling

KW - Transforming growth factor β receptor type 1 6A/9A

UR - http://www.scopus.com/inward/record.url?scp=77952367661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952367661&partnerID=8YFLogxK

U2 - 10.1073/pnas.1002816107

DO - 10.1073/pnas.1002816107

M3 - Article

VL - 107

SP - 7858

EP - 7862

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 17

ER -